TORONTO--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Phase 2b data with azeliragon in early stage Alzheimer’s disease were reviewed in an oral presentation at the 2016 Alzheimer’s Association International Conference (AAIC). Data presented show that azeliragon 5mg/day was effective in delaying the time to cognitive deterioration when compared to placebo in patients with mild Alzheimer’s disease.
